Insight Molecular Diagnostics (IMDX) Treasury Shares (2019 - 2026)

Insight Molecular Diagnostics has disclosed Treasury Shares across 8 years of filings, most recently posting $684000.0 for Q1 2026.

• Treasury Shares for Q1 2026 came in at $684000.0, down 9.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $684000.0 (down 9.52% YoY), and the FY2025 annual result was $852000.0, up 752.0% from the prior year.
• Treasury Shares came in at $684000.0 for Q1 2026 at Insight Molecular Diagnostics, down from $852000.0 in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $1.5 million in Q3 2022 to a low of $5000.0 in Q3 2023.
• The 5-year median for Treasury Shares is $581000.0 (2022), against an average of $471000.0.
• Across the five-year window, Treasury Shares sank 99.66% in 2023 and soared 15020.0% in 2025, its largest moves.
• Insight Molecular Diagnostics' Treasury Shares stood at $22000.0 in 2022, then plunged by 77.27% to $5000.0 in 2023, then surged by 1900.0% to $100000.0 in 2024, then surged by 752.0% to $852000.0 in 2025, then declined by 19.72% to $684000.0 in 2026.
• The last three Treasury Shares figures came in at $684000.0 (Q1 2026), $852000.0 (Q4 2025), and $917000.0 (Q3 2025), per Business Quant data.